Literature DB >> 12435710

In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole.

Evangelos J Giamarellos-Bourboulis1, Lazaros Karnesis, Irene Galani, Helen Giamarellou.   

Abstract

The time-kill effect of moxifloxacin on 20 genetically distinct isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole was studied. The majority (80%) were killed by a concentration equivalent to four times the MIC; the MIC induced a transient decrease in bacterial counts at 4 h, followed by regrowth. No effect was detected in four isolates. These results merit further clinical consideration.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12435710      PMCID： PMC132774          DOI： 10.1128/AAC.46.12.3997-3999.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy.

Authors:  A Soman; D Honeybourne; J Andrews; G Jevons; R Wise
Journal:  J Antimicrob Chemother       Date:  1999-12       Impact factor: 5.790

2.  Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains.

Authors:  S Valdezate; A Vindel; E Loza; F Baquero; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia.

Authors:  K Weiss; C Restieri; E De Carolis; M Laverdière; H Guay
Journal:  J Antimicrob Chemother       Date:  2000-03       Impact factor: 5.790

4.  Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999).

Authors:  A C Gales; R N Jones; K R Forward; J Liñares; H S Sader; J Verhoef
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

5.  Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals.

Authors:  S Tsiodras; D Pittet; Y Carmeli; G Eliopoulos; H Boucher; S Harbarth
Journal:  Scand J Infect Dis       Date:  2000

6.  Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.

Authors:  H Stass; D Kubitza
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

7.  Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods.

Authors:  D J Biedenbach; M A Croco; T J Barrett; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-06       Impact factor: 3.267

8.  Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia.

Authors:  G Berg; N Roskot; K Smalla
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

9.  Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.

Authors:  L Zhang; X Z Li; K Poole
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

10.  SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia.

Authors:  L Zhang; X Z Li; K Poole
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191
View more
  8 in total

1.  Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia.

Authors:  J W Betts; L M Phee; N Woodford; D W Wareham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-30       Impact factor: 3.267

2.  Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999-2006.

Authors:  M-S Hsu; C-H Liao; Y-T Huang; C-Y Liu; C-J Yang; K-L Kao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-03       Impact factor: 3.267

Review 3.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

4.  Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study.

Authors:  E J Giamarellos-Bourboulis; D Plachouras; A Tzivra; V Kousoulas; N Bolanos; M Raftogiannis; I Galani; I Dontas; A Dionyssiou-Asteriou; H Giamarellou
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

5.  Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem.

Authors:  Asma Marzouq Al-Jasser
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-09-18       Impact factor: 3.944

6.  Effects of Fluoroquinolones and Azithromycin on Biofilm Formation of Stenotrophomonas maltophilia.

Authors:  Aihua Wang; Qinqin Wang; Timothy Kudinha; Shunian Xiao; Chao Zhuo
Journal:  Sci Rep       Date:  2016-07-13       Impact factor: 4.379

7.  In vitro Antibacterial Activity and Resistance Prevention of Antimicrobial Combinations for Dihydropteroate Synthase-Carrying Stenotrophomonas maltophilia.

Authors:  Jin Zhao; Yan Huang; Jian Li; Bo Zhang; Zhiwei Dong; Dong Wang
Journal:  Infect Drug Resist       Date:  2022-06-13       Impact factor: 4.177

8.  Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.

Authors:  Chuanqi Wei; Wentao Ni; Xuejiu Cai; Jin Zhao; Junchang Cui
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.